EODData

MEMBERSHIP REGISTER LOG IN

FRA, 4A3: immatics biotechnologies GmbH

28 Jan 2026
LAST:

8.250

CHANGE:
 0.17		OPEN:
8.230		HIGH:
8.250		ASK:
0.000		VOLUME:
500
CHG(%):
2.04		PREV:
8.085		LOW:
8.230		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
28 Jan 268.2308.2508.2308.250500
27 Jan 268.0858.0858.0858.085450
26 Jan 268.2858.2858.0058.005450
23 Jan 268.5408.7508.5408.7501.0K
22 Jan 268.3008.3008.3008.3001.8K
21 Jan 268.3558.3558.3558.3551.8K
20 Jan 268.3258.3258.3258.3251.8K
19 Jan 268.3508.5608.3508.4851.8K
16 Jan 268.4358.6558.4358.655200
15 Jan 268.3758.6508.3658.500800

PROFILE

Name:immatics biotechnologies GmbH
About:Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Sector:Healthcare
Industry:Biotechnology
Address:Paul-Ehrlich-Strasse 15, Tübingen, Germany, 72076
Website:https://www.immatics.com
ISIN:NL0015285941

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:27.93 
PEG Ratio:0.07 
Price to Sales:13.73 
Price to Book:2.53 
Profit Margin:-1.42 
Operating Margin:-10.53 
Return on Assets:-0.16 
Return on Equity:-0.30 
Revenue:84.76M 
Shares:121.56M 
Market Cap:1.003B 

TECHNICAL INDICATORS

MA5:8.280.3%
MA10:8.371.5%
MA20:8.331.0%
MA50:8.634.6%
MA100:7.874.8%
MA200:6.3130.8%
STO9:32.89
STO14:42.20
RSI14:49.08
WPR14:-57.80
MTM14:0.37
ROC14:0.05 
ATR:0.27 
Week High:8.756.1%
Week Low:8.013.1%
Month High:9.0810.1%
Month Low:7.7830.8%
Year High:10.0722.1%
Year Low:3.07168.8%
Volatility:8.96